Iratumumab

Drug Profile

Iratumumab

Alternative Names: Anti-CD30 antibody 5F11; MDX-060; Monoclonal antibody 5F11

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Medarex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Sep 2009 Discontinued - Phase-II for Hodgkin's disease in USA (IV)
  • 30 Sep 2009 Discontinued - Phase-II for Lymphoma in USA (IV)
  • 30 Sep 2009 Discontinued - Phase-II for Non-Hodgkin's lymphoma in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top